| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CD20 on B Cells
MessageSendout, Mayo test code: CD20B
Test Code
LAB1188
Alias/See Also
CD20, B-Cells
CD20B
CD20B
CPT Codes
86355, 86356
Preferred Specimen
3 mL whole blood from a lavender EDTA tube
Minimum Volume
1 mL
Other Acceptable Specimens
Pink EDTA tube
Instructions
1. Send whole blood specimen in original tube. Secondary aliquot tubes will be rejected.
2. Testing will be canceled if the specimen is not received ambient.
3. For serial monitoring, it is recommended that specimens are collected at the same time of day.
2. Testing will be canceled if the specimen is not received ambient.
3. For serial monitoring, it is recommended that specimens are collected at the same time of day.
Transport Container
Original tube
Transport Temperature
Ambient
Specimen Stability
Ambient (preferred): 4 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Secondary aliquot tube: Reject
Gross lipemia: Reject
Secondary aliquot tube: Reject
Methodology
Flow Cytometry
FDA Status
Approved
Setup Schedule
Monday through Sunday
Resulted Monday through Friday
Resulted Monday through Friday
Report Available
1-2 days
Limitations
Timing and consistency in timing of blood collection is critical when serially monitoring patients for lymphocyte subsets.
Reference Range
Included with report
Clinical Significance
Evaluation of CD19 deficiency in patients with a suspected CD19 deficiency (humoral immunodeficiency)
Confirming complete absence of B cells in suspected primary humoral immunodeficiencies using both CD19 and CD20 markers
Assessing therapeutic B-cell depletion quantitatively (absolute counts of cells/mcL) in any clinical context, including malignancies, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and membranous glomerulonephritis among others, and treatment or prevention of acute humoral rejection in positive crossmatch renal transplant recipients
This test is not useful for assessing whether B cells express the target molecule (CD20) in the context of initiating therapeutic monoclonal anti-CD20 antibody therapy (rituximab, ofatumumab, and tositumomab) for any of the hematological malignancies, or in other clinical contexts, such as autoimmunity.
Confirming complete absence of B cells in suspected primary humoral immunodeficiencies using both CD19 and CD20 markers
Assessing therapeutic B-cell depletion quantitatively (absolute counts of cells/mcL) in any clinical context, including malignancies, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and membranous glomerulonephritis among others, and treatment or prevention of acute humoral rejection in positive crossmatch renal transplant recipients
This test is not useful for assessing whether B cells express the target molecule (CD20) in the context of initiating therapeutic monoclonal anti-CD20 antibody therapy (rituximab, ofatumumab, and tositumomab) for any of the hematological malignancies, or in other clinical contexts, such as autoimmunity.
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
CD20 on B Cells, Blood
